Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - valaciclovir hydrochloride, quantity: 611.22 mg (equivalent: valaciclovir, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of ophthalmic zoster. for the treatment of recurrent herpes labialis (cold sores). for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes. reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with vaclovir, it is recommended that patients use safer sex practices (see section 4.4). prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - citalopram hydrobromide, quantity: 12.49 mg (equivalent: citalopram, qty 10 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; lactose monohydrate; magnesium stearate; microcrystalline cellulose; maize starch; copovidone; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - citalopram hydrobromide, quantity: 24.98 mg (equivalent: citalopram, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; maize starch; copovidone; microcrystalline cellulose; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - for treatment of major depression

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - citalopram hydrobromide, quantity: 49.96 mg (equivalent: citalopram, qty 40 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; maize starch; lactose monohydrate; croscarmellose sodium; copovidone; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - citalopram hydrobromide, quantity: 12.49 mg (equivalent: citalopram, qty 10 mg) - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; copovidone; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; titanium dioxide; hypromellose; macrogol 400 - treatment of major depression

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - paroxetine hydrochloride, quantity: 22.2 mg (equivalent: paroxetine, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; sodium starch glycollate; lactose; hyprolose; hypromellose; macrogol 8000; titanium dioxide - treatment of major depression and prevention of relapse of depressive symptoms. treatment of obsessive compulsive disorder (ocd) and prevention of relapse of ocd. treatment of panic disorder and prevention of relapse of panic disorder. treatment of social anxiety disorder / social phobia. treatment of generalised anxiety disorder. treatment of post-traumatic stress disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - ambrisentan, quantity: 5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; microcrystalline cellulose; lactose monohydrate; titanium dioxide; purified talc; allura red ac aluminium lake; polyvinyl alcohol; macrogol 3350; lecithin - volibris is indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), -pulmonary arterial hypertension associated with connective tissue disease (pah-ctd), in patients with who functional class ii, iii or iv symptoms. volibris in combination with tadalafil is indicated for the treatment of who group 1 pulmonary arterial hypertension in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - ambrisentan, quantity: 10 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; titanium dioxide; purified talc; allura red ac aluminium lake; polyvinyl alcohol; macrogol 3350; lecithin - volibris is indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), -pulmonary arterial hypertension associated with connective tissue disease (pah-ctd), in patients with who functional class ii, iii or iv symptoms. volibris in combination with tadalafil is indicated for the treatment of who group 1 pulmonary arterial hypertension in patients with who functional class ii, iii or iv symptoms.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - valaciclovir, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; indigo carmine aluminium lake; crospovidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 6000; macrogol 400 - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. treatment of ophthalmic zoster. treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes in immunocompromised patients with creatinine clearance of > 15 ml/min. for the reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with valaciclovir, it is recommended that patients use safer sex practices (see precautions). for prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

cns pharma pty ltd - escitalopram oxalate, quantity: 25.54 mg (equivalent: escitalopram, qty 20 mg) - tablet, film coated - excipient ingredients: purified talc; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; croscarmellose sodium; titanium dioxide; hypromellose; purified water; macrogol 400 - treatment of major depression. treatment of social anxiety disorder (social phobia). treatment of generalised anxiety disorder.